Advances in stem cell technology, combined with the increasing prevalence of chronic diseases, are driving rapid growth in the regenerative medicine category, which is predicted to generate $39.33 billion in revenue by 2023.
The regenerative medicine category is predicted to generate $39.33 billion in revenue by 2023, with the fastest growth expected in cell therapy.
“There’s a little over 1,200 clinical trials worldwide, and about half of those are in the US. Over 100 of those are in phase III, so we’re getting really close to getting more approved.”
A 2018 study by Deloitte suggested that more than 2.4 million manufacturing jobs in the US would remain unfilled in 2028 because of the widening – and often generational – skills gap.
To successfully increase speed-to-market for gene therapies, having a defined CQV (Commissioning, Qualification, and Validation) strategy is critical to project success. In this webinar co-sponsored by Precision ADVANCE and Project Farma, our panel of industry experts discuss tips for delivering efficient, reliable, GMP-compliant facilities and processes specific to gene therapy.
We are in the midst of a therapeutic revolution. An H1 report released by Alliance for Regenerative Medicine (ARM) highlights a record-breaking year, with over 1,320 ongoing clinical trials worldwide and 1000+ therapeutic developers. As 2021 comes to an end, we are on track to expect the highest number of advanced therapy regulatory approvals, when compared to previous years.
When building a cell therapy manufacturing facility, having a defined CQV (Commissioning, Qualification, and Validation) strategy is critical to project success. In this webinar co-sponsored by Precision ADVANCE and Project Farma, our panel of industry experts discuss tips for delivering efficient, reliable, GMP-compliant facilities and processes specific to cell therapy.
Is “flexible manufacturing” just another empty buzz concept concocted by the biopharma equipment marketing community, or does it demonstrate real benefit? Business of Biotech Podcast: Episode 69, “Foundations of Flexible Manufacturing” features insights from Tony Khoury (EVP of Project Farma) and Brian Winstead (Senior Director, Facilities & Engineering at Sarepta Therapeutics) on what flexible manufacturing means, when it works and when it doesn’t.
Business of Biotech Podcast: Episode 68, “The CDMO Capacity Crunch” features insights from Anshul Mangal (President of Project Farma and Precision ADVANCE), Audrey Greenberg (Co-founder of Discovery Labs), and Sumit Verma (SVP, Commercial Manufacturing at Iovance) on CDMO buildouts, limited manufacturing space, and the expertise needed to meet timelines, satisfy investors, and drive competitive advantage.